Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive

Isomorphic Labs, AI Drug-discovery platform which was Out of Google’s Dipmind In 2021, the external capital raised for the first time. Google’s parents, with the participation of the existing investor alphabet, were governed by Thrive Capital, $ 600 million round, It saysThe

This fund will accelerate the development of the AI ​​drug design engine of Isomorphic and will support the company’s target of bringing its discovered drugs in clinical trials.

Isomorphic labs were founded by Demis Hassabis, co-founder of the Dipmind, earned the Dipmind software for the invention of AI drug, an AI model with Alfafold that predicts the three-dimensional structure of the protein.

Last year, Isomorphic Labs have secured strategic partnerships with Eli Lily and Novartis, possible Generated up to $ 3 billion In case of providing milestones for access to AI model.

Hasbis said New York Times Although the capital of isomorphic labs does not require capital, the additional funds will help the appointment of top research scientists.

For their work in Alfafold, Husabis and Depthmind Researcher John John Jumper was one of the three scientists who received Nobel Prize in Chemistry In 2024.